Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel versus docetaxel alone as second-line treatment for advanced non-small cell lung cancer
ChiCTR1900023723Phase 4Recruiting
- Sponsor
- Nanyang Central Hospital
- Start
- Jun 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nanyang Central Hospital. Primary endpoint: progression-free survival. Started Jun 2019; status: recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900023723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023723.